Pacira BioSciences, Inc. PCRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.14M-27.0% | $7.03M— | —— | —— | —— | ||
| $91.19M+0.2% | $91.02M+0.1% | $90.92M+1.0% | $89.99M+10.4% | $81.53M+3.5% | ||
| $56.49M-1.8% | $57.5M+2.2% | $56.27M+1.3% | $55.52M+5.6% | $52.57M+2.7% | ||
| —— | —— | $13.73M+103% | $6.77M-63.5% | $18.56M-10.0% | ||
| $2.73M-9.6% | $3.02M-8.0% | $3.28M-6.1% | $3.49M+2.5% | $3.41M+5.8% | ||
| $20.87M+94.3% | $10.74M-26.4% | $14.59M+52.5% | $9.57M+208% | $3.11M-59.9% | ||
| —— | —— | $45.8M+2.4% | $44.72M+20.9% | $36.97M+76.7% | ||
| -$9M-60.7% | -$5.6M— | —— | —— | —— | ||
| -$8.15M-219% | $6.85M— | —— | —— | —— | ||
| —— | —— | —— | $17.27M+186% | $6.04M+9,997% | ||
| —— | —— | —— | $14.41M+216% | $4.57M+68.3% | ||
| —— | —— | —— | —— | —— | ||
| $142.22M-6.4% | $151.99M+7.5% | $141.44M+5.1% | $134.52M-23.5% | $175.75M-7.2% | ||
| $9.51M-38.0% | $15.33M-11.0% | $17.23M-1.3% | $17.46M+6.8% | $16.35M+53.7% | ||
| —— | —— | —— | —— | $16.7M— | ||
| $71.41M-49.4% | $141.04M-11.1% | $158.65M-28.3% | $221.12M-16.8% | $265.79M+5.4% | ||
| $227.06M-17.1% | $273.81M+0.1% | $273.61M+13.8% | $240.53M+17.1% | $205.46M+14.4% | ||
| $144.55M+45.3% | $99.48M+24.7% | $79.78M+599% | -$16M+82.9% | -$93.38M-12.1% | ||
| $198.37M+33.7% | $148.33M+39.5% | $106.33M+70.0% | $62.54M+234% | $18.75M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| $9.79M+74.3% | $5.62M+1.2% | $5.55M-0.4% | $5.58M+735% | $668K+36.0% | ||
| -$426.03M-15.3% | -$369.63M— | —— | —— | —— | ||
| -$39K+49.4% | -$77K-123% | $337K+65.2% | $204K— | —— | ||
| -$150.26M-16.3% | -$129.19M-31.3% | -$98.38M-280% | $54.52M-45.8% | $100.65M-19.2% | ||
| $14.12M-7.4% | $15.24M-2.4% | $15.62M-3.1% | $16.12M+13.8% | $14.16M-8.1% | ||
| —— | —— | $10.39M-28.8% | $14.59M+26.3% | $11.55M+4.8% | ||
| —— | —— | —— | —— | $7.48M+0.7% | ||
| —— | —— | —— | —— | $3.28M+1.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0+100% | -$541.25K+50.0% | -$1.08M+33.3% | -$1.62M+25.0% | ||
| —— | $6.85M-21.7% | $8.75M-17.8% | $10.64M-15.1% | $12.54M-13.1% | ||
| —— | —— | —— | $17.27M+186% | $6.04M+9,997% | ||
| —— | —— | —— | —— | -$5.72M-2,525% | ||
| $71.41M-49.4% | $141.04M-11.1% | $158.65M-28.3% | $221.12M-16.8% | $265.79M+5.4% | ||
| $227.06M-17.1% | $273.81M+0.1% | $273.61M+13.8% | $240.53M+17.1% | $205.46M+14.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $1.79M+33.3% | $1.34M+50.0% | $896K+100% | $448K— | ||
| —— | —— | —— | —— | —— | ||
| $132.71M-2.9% | $136.66M+10.0% | $124.2M+6.1% | $117.07M-26.6% | $159.4M-10.8% | ||
| $132.71M-2.9% | $136.66M+10.0% | $124.2M+6.1% | $117.07M-26.6% | $159.4M-10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacira BioSciences, Inc. generate?
- Pacira BioSciences, Inc. (PCRX) generated $142.2M in operating cash flow over the trailing twelve months.
- What is Pacira BioSciences, Inc.'s free cash flow?
- After $9.5M of capital expenditures, Pacira BioSciences, Inc.'s free cash flow was $132.7M over the trailing twelve months, down 16.8% year over year.
- Where does Pacira BioSciences, Inc.'s cash flow data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
